Michael Yu, Innovent CEO (Anthony Kwan/Bloomberg via Getty Images)
August 16, 2021 06:50 AM EDT
R&D
China

As US re­view of Eli Lil­ly-part­nered PD-1 gets un­der­way, In­novent touts an­oth­er front­line win in Chi­na

Amber Tong

When Eli Lil­ly inked a $1 bil­lion-plus deal to grab ex-Chi­na com­mer­cial­iza­tion rights for In­novent’s PD-1 Tyvyt (sin­til­imab), the part­ners hailed the “clin­i­cal pro­file …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times